Flyrcado, a PET tracer for coronary artery disease, is set to be launched in the U.S. market in early 2025, with availability ...

Ryan Zimmerman has given his Buy rating due to a combination of factors including the recent FDA approval of GE Healthcare Technologies Inc’s Flyrcado, a PET radiotracer injection that offers ...

Larry Biegelsen has given his Buy rating due to a combination of factors related to the potential market impact of GE Healthcare Technologies Inc’s new PET tracer, Flyrcado. This new tracer has ...

The U.S. Food and Drug Administration (FDA) has approved flurpiridaz F-18 (Flyrcado; GE Healthcare), a first-of-its-kind positron emission tomography (PET) imaging agent, for use in adult patients ...

GE HealthCare has received approval for Flyrcado, its enhanced diagnosis tool for coronary heart disease, from the Food and Drug Administration. The company said on Friday that Flyrcado ...

The agent, called Flyrcado (flurpiridaz F 18), offers higher diagnostic efficacy than the current standard of care procedure in nuclear cardiology and could expand access to PET myocardial ...

(European Heart Journal) FDA approved flurpiridaz F-18 (Flyrcado), a radiotracer for positron emission tomography myocardial ...

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...

Recently, GE HealthCare (NASDAQ:GEHC) announced FDA’s approval of its Flyrcado (flurpiridaz F 18), a new diagnostic agent for heart health. The product is designed for the detection of coronary ...

GE HealthCare Technologies, Inc. GEHC announced that it has received FDA approval for Flyrcado (flurpiridaz F 18), a breakthrough positron emission tomography myocardial perfusion imaging (PET MPI ...